SIH Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

SIH Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,738	Closed	-$208K	–	277
2025 Q1	$208K	Buy	+5,738	New	+$239K	0.01%	223

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SIH Partners's RARE Position: Q2 2025 in Review

SIH Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 5,738 shares — an estimated $208K sold.

SIH Partners first reported a position in RARE in Q1 2025 and held it in 1 quarter. The position peaked at $208K in Q1 2025. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

SIH Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 5,738 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $208K.
SIH Partners first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and held it in 1 quarter.
SIH Partners's Ultragenyx Pharmaceutical position peaked at $208K in Q1 2025.
309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.